Home | Welcome to Contract Pharma   
Last Updated Saturday, November 22 2014

Topics - Biologics, Proteins, Vaccines

Refine by Date:
From: To:
Published November 21, 2014
Increased production capacity to support maturing biologics pipeline Read More »
Published November 20, 2014
Incorporates multiple technologies aimed at greater speed and efficiency Read More »
Published November 14, 2014
The investment, upwards of $900 million, will support multiple therapies Read More »
Biosimilar Development: Where Are We Now?
By Fiona Greer , SGS Life Science Services
Published November 13, 2014
Recent developments indicate a growth surge. Read More »
Published November 7, 2014
Acquires Integra Companies and STI Components Read More »
Published October 31, 2014
To produce commercial quantities of a second biologic at Lonza’s Portsmouth facility Read More »
Published October 30, 2014
Will collaborate with Pontifax to invest in technologies to advance capabilities Read More »
Published October 28, 2014
Enhances capacity and capabilities for cell culture testing Read More »
Published October 28, 2014
Becomes second largest player in the $4 billion global flu vaccine industry Read More »
Published October 23, 2014
Contract manufacturing market has grown 10% the past three years Read More »
Published October 22, 2014
Supply of the new product will be available in early December Read More »
Published October 21, 2014
Will begin large-scale manufacturing Read More »
Published October 21, 2014
Adds new immunotherapy platforms for cancer research Read More »
Published October 16, 2014
Will explore various combinations of agents leveraging Immune Design's GLAAS platform Read More »
Published October 7, 2014
Offers a range of advanced biomedical technologies for clinical and commercial volumes Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On